Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | KIT | P10721 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 15/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584007 | 0.93 | OPRK1 (0.38) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL4583653 | 0.91 | MAPK14 (0.45) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL4584121 | 0.85 | MAPK14 (0.46) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL4582146 | 0.85 | MAPK14 (0.40) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL4583028 | 0.82 | MEN1 (0.51) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL4582588 | 0.82 | MAPK14 (0.44) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL4583307 | 0.81 | MAPK14 (0.43) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL4582797 | 0.80 | MAPK14 (0.42) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL4583873 | 0.78 | MAPK14 (0.40) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL4583340 | 0.78 | MALT1 (0.45) | PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | claimed |
| EP-1903037-A1 | 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
| EP-1903037-A1 | 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | PTGER2, PTGER1, PTGES2 | MAPK14 3040/4885KIT 2834/4885KDR 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.